TickerFacts.

Arcus Biosciences, Inc. (RCUS): Revenue

Annual figures by period end, from SEC filings.

$247.00M
Year ended 2025-12-31
$117.00M
Trailing 12 months to 2026-06-30
+30.2%
3-year compound annual growth
+25.9%
5-year compound annual growth
$383.00M2017-12-31: $1.41M2018-12-31: $8.35M2019-12-31: $15.00M2020-12-31: $78.00M2021-12-31: $383.00M2022-12-31: $112.00M2023-12-31: $117.00M2024-12-31: $258.00M2025-12-31: $247.00M$247.00M
2017-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$247.00M-4.3%2026-02-25, From 2025-01-01
2024-12-31$258.00M+120.5%2026-02-25, From 2024-01-01
2023-12-31$117.00M+4.5%2026-02-25, From 2023-01-01
2022-12-31$112.00M-70.8%2025-02-25, From 2022-01-01
2021-12-31$383.00M+391.0%2024-02-21, From 2021-01-01
2020-12-31$78.00M+420.0%2023-02-28, From 2020-01-01
2019-12-31$15.00M+79.6%2020-03-05, From 2019-01-01
2018-12-31$8.35M+491.2%2020-03-05, From 2018-01-01
2017-12-31$1.41Mn/a2019-03-05, From 2017-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Arcus Biosciences, Inc. (RCUS)2025-12-31$247.00M-4.3%
Keros Therapeutics, Inc. (KROS)2025-12-31$244.06Mn/m
Schrodinger, Inc. (SDGR)2025-12-31$255.87M+23.3%
Akebia Therapeutics, Inc. (AKBA)2025-12-31$236.20M+47.5%
Anaptysbio, Inc (ANAB)2025-12-31$234.60M+157.0%
Arvinas, Inc. (ARVN)2025-12-31$262.60M-0.3%
Puma Biotechnology, Inc. (PBYI)2025-12-31$228.37M-0.9%
Ligand Pharmaceuticals Inc (LGND)2025-12-31$268.09M+60.4%
Vireo Growth Inc. (VREOF)2025-12-31$268.77M+170.4%

Compare RCUS, KROS, SDGR, AKBA side by side · Screen every company in Pharmaceutical Preparations ↗